Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Vonoprazan Fumarate

SKU: orb1940457

Description

Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.(In Vitro):The inhibitory activity of Vonoprazan Fumurate was unaffected by ambient pH. The inhibition by Vonoprazan Fumurate was reversible and achieved in a K(+)-competitive manner, quite different from that by lansoprazole. Vonoprazan Fumurate exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner.(In Vivo):Vonoprazan Fumurate, at a dose of 4 mg/kg (as the free base) orally, completely inhibited basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats, and its effect on both was stronger than that of lansoprazole. Vonoprazan Fumurate increased the pH of gastric perfusate to a higher value than did lansoprazole or SCH28080, and the effect of Vonoprazan Fumurate was sustained longer than that of lansoprazole or SCH28080.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number881681-01-2
MW461.46
Purity>98% (HPLC)
FormulaC21H20FN3O6S
SMILESOC(=O)\C=C\C(O)=O.CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1
TargetProton Pump
SolubilityIn Vitro: DMSO : 50 mg/mL (108.35 mM)

Bioactivity

In Vivo
Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s. c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats. Animal model: Male 7-or 8-week-old Sprague-Dawley rat. Dosage: 0.5, 1, 2, and 4 mg/kg. Administration: Oral administration. Result: Inhibited basal gastric acid secretion in a dose-dependent manner.
In Vitro
Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+, K+-ATPase activity in a concentration-dependent manner. Vonoprazan does not inhibit Na+, K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+, K+-ATPase activity.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

TAK-438 | TAK 438 | TAK438 | Vonoprazan Fumurate

Similar Products

  • Vonoprazan fumarate [orb1305537]

    100.00% (May vary between batches)

    1260141-27-2

    461.46

    C17H16FN3O2S·C4H4O4

    100 mg, 250 mg, 1 g
  • Vonoprazan Fumarate [orb1306422]

    >99.99% (May vary between batches)

    881681-01-2

    461.46

    C21H20FN3O6S

    500 mg, 1 g, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

100 mg
$ 80.00
200 mg
$ 120.00
500 mg
$ 240.00